三个皮匠报告
最新
报告分类 研搜
热门标签
BETA
政策库
自研报告
new
入驻
搜索
当前位置：首页 >英文主页 >中英对照 > 报告详情

Biomedtracker：2025美国临床肿瘤学会（ASCO）年会深度解析报告（英文版）（266页）.pdf

上传人： Y**** 编号：712920 2025-06-12 266页 6MB

下载：

1、 2025 Biomedtracker Datamonitor Healthcare Post-ASCO Report June 2025 Brought to you by:Summary The 2025 Annual Meeting of the American Society of Clinical Oncology(ASCO)was held in Chicago from May 30th-June 3rd,2025.This post-meeting report features commentary from our analysts on key presentation

2、s at the conference as well as a compilation of all data events added to Biomedtracker in conjunction with the meeting.As a reminder,our ASCO coverage will continue throughout the conference and beyond.Our coverage will include:June 16 Post-ASCO Webinar June 20 Post-ASCO Podcast About the Author Bio

3、medtracker is an independent research service that offers proprietary clinical assessments and patient-based revenue forecasts of developmental drugs within a comprehensive and intuitive drug information database.Clients from the pharmaceutical,biotech,and investment industries rely on Biomedtracker

4、 for its insight on the likelihood of approval,commercial potential,and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.Over the last several years,Biomedtracker has become the leader in providing objective information alongsi

5、de evidence based clinical assessments and investment research on pipeline drugs worldwide.For more information on getting direct access to Biomedtracker,please email .Disclaimer Copyright 2025 Evaluate,a Norstella company This report is published by Evaluate(the Publisher).This report contains info

6、rmation from reputable sources and although reasonable efforts have been made to publish accurate information,you assume sole responsibility for the selection,suitability and use of this report and acknowledge that the Publisher makes no warranties(either express or implied)as to,nor accepts liabili

word格式文档无特别注明外均可编辑修改，预览文件经过压缩，下载原文更清晰！
三个皮匠报告文库所有资源均是客户上传分享，仅供网友学习交流，未经上传用户书面授权，请勿作商用。
根据报告的内容，本文主要概括了2025年美国临床肿瘤学会(ASCO)年会后发布的报告，包括以下关键点： 1. Ascentage Pharma的lisaftoclax在急性髓细胞性白血病(AML)和骨髓增生异常综合征(MDS)的I/II期研究中，与阿扎胞苷联合使用，在难治/复发AML患者中显示出39%的总体响应率，在TN-MDS/CMML患者中显示出64%的总体响应率。 2. Kura Oncology的ziftomenib在NPM1突变型AML的Ib/II期研究中，在难治/复发患者中显示出25%的完全缓解率。 3. Astellas的Padcev加Keytruda在膀胱癌的III期研究中，与化疗相比，在完全响应者中显示出更长的无进展生存期和总生存期。 4. BMS的Opdivo加Yervoy在膀胱癌的III期研究中，与化疗相比，在一线治疗中未达到总体生存的显著性差异。 5. Gilead的Trodelvy在膀胱癌的II期研究中，与阿维鲁单抗相比，作为一线维持治疗显示出更长的无进展生存期。
Lisaftoclax治疗AML效果如何？ Ziftomenib治疗NPM1突变AML效果如何？ Padcev+Keytruda治疗膀胱癌效果如何？
全行业研究报告分享下载平台
  • 0731-84720580
  • 商务合作：really158d
  • 友链申请 (QQ)：1737380874
关于我们
更多
关于我们
三个皮匠报告微信公众号
三个皮匠报告微信小程序
扫码咨询商务合作事宜
友情链接：
营销自动化 亿欧智库 微播易 阿里妈妈
copyright@2008-2013 长沙思想领动信息技术有限公司版权所有        网站备案/许可证号：湘B2-20190120 | 工信部备案号：湘ICP备2023027541号-2 | 公安备案号：湘公网安备43010402001071号
客服
商务合作
小程序
服务号
折叠